Dr Gretchen Poortinga
Honorary (Senior Fellow)
The Sir Peter MacCallum Department of Oncology
51 Scholarly works
1 Projects
HIGHLIGHTS
2024
Journal article
CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci
DOI: 10.3390/biomedicines120715142024
Journal article
Targeting the ribosome to treat multiple myeloma
DOI: 10.1016/j.omton.2024.2007712020
Journal article
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis
DOI: 10.15252/embj.20201051112020
Journal article
rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
DOI: 10.3389/fcell.2020.005682020
Conference Proceedings
Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.
DOI: 10.1158/1557-3265.ovca19-pr132020
Journal article
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
DOI: 10.1038/s41467-020-16393-42019
Journal article
Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation
DOI: 10.1038/s42003-019-0284-y
RECENT SCHOLARLY WORKS
2019
Conference Proceedings
The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans
DOI: 10.1182/blood-2019-1217132019
Journal article
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
DOI: 10.1073/pnas.19013231162019
Journal article
First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: Results of a phase I dose-escalation study
DOI: 10.1158/2159-8290.CD-18-1455
RECENT PROJECTS
2016
Research Grant
Elucidating Mechanisms of Resistance to Therapeutic Inhibition of Rna Polymerase I Transcription